Table 3. Multivariate analysis of overall survival (cox-regression).
N = 9210 | Hazard ratio | 95% Confidence interval | p-value | |
Age | 1.061 | 1.058-1.065 | <0.001 | |
Sex | Male | reference | ||
Female | 0.864 | 0.802-0.932 | <0.001 | |
Race | White patients | reference | ||
Black patients | 1.740 | 1.232 - 2.455 | 0.006 | |
Other00 | 0.929 | 0.708-1.221 | 0.599 | |
Hispanic origin | Non-Spanish, Non-Hispanic patients | reference | ||
Hispanic patients | 1.159 | 0.998 - 1.346 | 0.056 | |
Insurance status | Not insured | reference | ||
Private insurance | 0.611 | 0.475-0.787 | <0.001 | |
Medicaid | 1.162 | 0.848-1.594 | 0.350 | |
Medicare | 0.638 | 0.494 - 0.824 | <0.001 | |
Other government | 0.557 | 0.356 - 0.870 | 0.010 | |
Treatment facility | Community cancer program | reference | ||
Comprehensive community cancer program | 0.691 | 0.433-0.861 | 0.040 | |
Academic/research program | 0.604 | 0.398-0.742 | 0.002 | |
Integrated network cancer program | 0.573 | 0.369-0.683 | <0.001 | |
Urban/rural (2020) | Metropolitan | reference | ||
Urban | 0.964 | 0.871-1.068 | 0.488 | |
Rural | 1.222 | 0.863-1.728 | 0.258 | |
Median household income (2020) | reference | |||
$57,857-$74,062 | 0.781 | 0.386 - 1.581 | 0.492 | |
$46,277-$57,856 | 0.714 | 0.354-1.440 | 0.347 | |
$74,063 | 0.683 | 0.340-1.375 | 0.286 | |
Percent without a high school degree | >=15.3% | reference | ||
9.1%-15.2% | 1.900 | 0.934-3.864 | 0.076 | |
5.0%-9.0% | 1.698 | 0.837-3.443 | 0.142 | |
<5.0% | 1.665 | 0.823-3.369 | 0.156 | |
Charlson–Deyo score | 0 | reference | ||
1 | 1.132 | 1.033-1.240 | 0.008 | |
2 | 1.521 | 1.299-1.781 | <0.001 | |
>=3 | 1.922 | 1.579-2.341 | <0.001 | |
Primary tumor location | Skin of the head or neck | reference | ||
Skin of trunk | 1.034 | 0.938-1.140 | 0.502 | |
Skin of the extremities | 0.803 | 0.738-0.873 | <0.001 | |
Overlapping lesion of skin or NOS | 0.914 | 0.786-1.063 | 0.243 | |
Stage | 0 | reference | ||
I | 0.667 | 0.391-1.138 | 0.137 | |
II | 1.030 | 0.606-1.750 | 0.914 | |
III | 1.501 | 0.878-2.565 | 0.138 | |
IV | 3.278 | 1.908-5.635 | <0.001 | |
Histology | Mixed epithelial and spindle cell melanoma | reference | ||
Spindle cell melanoma, NOS | 1.024 | 0.920-1.140 | 0.664 | |
Behavior | In-situ and synonymous with in-situ | reference | ||
Invasive | 1.044 | 0.405-2.688 | 0.930 | |
Surgery | Not performed | reference | ||
Performed | 0.841 | 0.750-0.943 | 0.003 | |
Radiation | Not performed | reference | ||
Performed | 1.257 | 1.146-1.379 | <0.001 | |
Immunotherapy | Not performed | reference | ||
Performed | 0.770 | 0.677-0.875 | <0.001 | |
Chemotherapy | Not performed | reference | ||
Performed | 1.604 | 1.370-1.877 | <0.001 |